65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016

  • ID: 3802785
  • Report
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Vical Incorporated
  • MORE
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016

Summary

‘65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016’, provides in depth analysis on 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted pipeline therapeutics.

The report provides comprehensive information on the 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus)
- The report reviews 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics and enlists all their major and minor projects
- The report assesses 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Vical Incorporated
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Overview

Therapeutics Development

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Stage of Development

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Therapy Area

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Indication

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Products Glance

Late Stage Products

Early Stage Products

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Companies

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Universities/Institutes

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Companies Involved in Therapeutics Development

Astellas Pharma Inc.

Atara Biotherapeutics, Inc.

Immunomic Therapeutics, Inc.

Vakzine Projekt Management GmbH

Vical Incorporated

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Drug Profiles

Anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CyMVectin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cytomegalovirus vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pp65 DC + Td - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPM-2001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Dormant Projects

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Discontinued Products

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Featured News & Press Releases

Dec 06, 2015: Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes, a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System

Nov 05, 2015: Atara Bio to Present Data on CMV-CTL at the American Society of Hematology Annual Meeting 2015

May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients

Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference

Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients

Jun 25, 2013: Vical And Astellas Initiate Phase III Trial Of ASP0113 Cytomegalovirus Vaccine

Apr 02, 2012: Astellas And Vical Advance Toward Phase III Trial Of TransVax CMV Vaccine Triggering $10m Milestone Payment To Vical

Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine

Jan 11, 2012: Vical Announces Online Publication Of Phase II Proof-Of-Concept Trial Results Of TransVax

Jul 14, 2011: Vical Announces Scientific Advances On CyMVectin At DNA Vaccines 2011 Conference

Jul 14, 2011: Vical Announces Scientific Advances For TransVax At DNA Vaccines 2011 Conference

May 19, 2011: Vical To Present TransVax And DNA Vaccines At ASGCT Conference

Apr 14, 2011: Vical Receives Key European Patent For TransVax Cytomegalovirus Vaccine

Mar 02, 2011: Vical Receives Positive Scientific Advice From EMA For TransVax Phase III Trial

Sep 13, 2010: Vical Announces Positive Results From Phase II Trial Of TransVax CMV Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 52List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Astellas Pharma Inc., H1 2016

Pipeline by Atara Biotherapeutics, Inc., H1 2016

Pipeline by Immunomic Therapeutics, Inc., H1 2016

Pipeline by Vakzine Projekt Management GmbH, H1 2016

Pipeline by Vical Incorporated, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 41List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Vical Incorporated
  • MORE
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes.

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

The author's latest report 65 kDa Phosphoprotein - Pipeline Review, H1 2016, outlays comprehensive information on the 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Astellas Pharma Inc.
Atara Biotherapeutics, Inc.
Immunomic Therapeutics, Inc.
Vakzine Projekt Management GmbH
Vical Incorporated
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll